NASDAQ, TSX: NVCN
VANCOUVER, Aug. 8, 2018 /PRNewswire/ - Neovasc, Inc.
("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX: NVCN), a leader in
the development of minimally invasive transcatheter mitral valve
replacement technologies, today announced that Fred Colen, President and Chief Executive
Officer of Neovasc, is now scheduled to present at the 38th Annual
Canaccord Genuity Growth Conference on Thursday, August 9th at 12:30 pm ET being held in Boston, Massachusetts.
A live audio webcast of the presentation will be available on
the Investors page of Neovasc's website at www.neovasc.com.
About Neovasc Inc.
Neovasc is a specialty medical
device company that develops, manufactures and markets products for
the rapidly growing cardiovascular marketplace. Its products
include the Neovasc Reducer™ (the "Reducer"), for the treatment of
refractory angina, which is not currently commercially available in
the United States and has been
commercially available in Europe
since 2015, and the Tiara™ (the "Tiara"), for the transcatheter
treatment of mitral valve disease, which is currently under
clinical investigation in the United
States, Canada and
Europe. For more information,
visit: www.neovasc.com.
View original
content:http://www.prnewswire.com/news-releases/neovasc-announces-updated-presentation-time-at-the-38th-annual-canaccord-genuity-growth-conference-300694188.html
SOURCE Neovasc Inc.